Formycon Secures Launch Timeline for Biosimilar Amid Financial Delays

Formycon finalizes FYB203 biosimilar launch dates in Europe and US for 2026 after patent settlement, but reports 2025 revenue miss and delayed financials.

The path to commercialization for Formycon's biosimilar version of Eylea is now clear in Europe, following a legal settlement. The company has resolved outstanding patent disputes with Regeneron Pharmaceuticals and Bayer Healthcare, finalizing the launch schedule for its aflibercept biosimilar, FYB203. However, this operational milestone is tempered by a delayed financial report and a revenue shortfall for the past year.

Commercial Launch Dates Finalized

The settlement guarantees market access for FYB203, marketed as AHZANTIVE® and Baiama®, across Europe and in key markets within Asia-Pacific and Latin America starting in May 2026. This agreement provides clarity for the company's commercialization partners. Formycon had previously secured a U.S. market entry timeline, targeting the fourth quarter of 2026. With these agreements, the launch framework for the two most significant sales regions is firmly established.

Financial Reporting and Revenue Miss

Despite the positive legal resolution, the company's shares face headwinds. The publication of the audited annual financial statements for 2025 has been postponed from late March to sometime in April 2026. Management cites the implementation of a new financial planning system and the associated validation processes as the reason for the delay.

Preliminary figures reveal a deviation from earlier forecasts:
- €45 million: Reported group revenue for 2025 (Previous forecast: €55 to €65 million)
- April 2026: New timeline for the audited annual report
- May 2026: Scheduled European launch for FYB203
- Q4 2026: Planned U.S. launch for FYB203

The lower revenue is attributed primarily to protracted negotiations for new partnership agreements. Specifically for its key pipeline asset, FYB206—a biosimilar candidate for Keytruda®—the company's leadership is prioritizing favorable financial terms over a swift deal closure.

Pipeline Progress Provides Forward Momentum

Looking ahead, Formycon is counting on its broader development pipeline to drive growth in the current and coming fiscal years. The spotlight remains on FYB206. In February 2026, the company announced positive data from the pivotal pharmacokinetic study for this candidate, successfully meeting its primary endpoint.

The company has already secured a partnership with Lotus Pharmaceutical for the distribution of FYB206 across significant portions of Asia. Investors are now awaiting the detailed annual report in April to assess the precise impact of the delayed partnerships on Formycon's cash position and its ability to fund ongoing research and development activities.